Members of SciFluor Life Sciences' Leadership Team Receive National Industry Recognition

Tobias Ritter, Ph.D. and Naina Bhasin, Ph.D. Honored for Innovative Leadership and Contributions to the Life Sciences Industry

Members of SciFluor Life Sciences' Leadership Team Receive National Industry Recognition

<0> Pure Communications, Inc.Kathryn Cook, 910-509-3976 </0>

, a drug discovery and development company harnessing the transformational power of fluorine to accelerate the development of innovative new therapeutics, today announced that the company’s scientific founder and a key executive have been named recipients of national industry awards.

Tobias Ritter, Ph.D., co-founder and chief scientific advisor of SciFluor, was named to the 2012 , an annual listing of the 100 most inspiring people in the life sciences industry. In addition, Naina Bhasin, Ph.D., vice president of business development, was selected to receive Pharmaceutical Executive Magazine’s , which recognizes leaders in the industry who drive innovation and bring new ideas to life.

“We are very proud that Tobias and Naina have been recognized in these publications for their talent, hard work and contributions to the industry,” said Arthur Hiller, chief executive officer of SciFluor. “They are both outstanding leaders who are extremely passionate about their work and we are honored to have them on the SciFluor team. With their insights and contributions, SciFluor is advancing our Fluoropeutics™ portfolio, developing novel F PET radiotracers, and working closely with potential partners to identify opportunities to drive new value in their drug development pipelines and enhance the efficiency of their discovery and development processes.”

Dr. Ritter is currently an associate professor in the Department of Chemistry and Chemical Biology at Harvard University, and founder of The Ritter Group, which focuses on fluorination chemistry for late-stage functionalization of complex natural and unnatural products and bimetallic transition metal redox catalysis. Prior to joining Harvard in 2006, he completed his post-doctoral fellowship at the California Institute of Technology. Dr. Ritter has won numerous prestigious awards, is a frequently invited lecturer and has authored more than two dozen scientific publications.

Prior to joining SciFluor, Dr. Bhasin served as vice president of business development and operations at The Hamner Institutes, a nonprofit research organization in Research Triangle Park, N.C. Previously, she served as director of the hepatic research registry for CellzDirect, Inc., an hepatic research company acquired by Invitrogen/Life Technologies. Dr. Bhasin earned a bachelor’s degree in cell and structural biology at the University of Illinois at Urbana-Champaign and a Ph.D. in cell and developmental biology from the University of North Carolina at Chapel Hill.

SciFluor is harnessing the transformational power of fluorine to enrich pipelines, optimize drug discovery and accelerate the clinical development of innovative new therapies. The company’s approach includes a proprietary portfolio of Fluoropeutics™, fluorine-enabled development candidates targeting a broad range of therapeutic indications, and novel F tracers for empowered PET imaging. SciFluor is funded by Allied Minds, a private equity-funded innovation company that forms, manages and builds startups based on early-stage technology developed at renowned U.S. universities and national labs. The company was founded in 2011 and is based in Cambridge, Mass. For more information, please visit .

Suggested Articles

In this week's EuroBiotech Report, GSK, Immatics strike cell therapy deal, Vifor buys priority review voucher and PharmaMar gets PDUFA date.

In our EuroBiotech roundup this week, U.K. creates life science zones, Genmab to ramp up R&D spending and Pfizer backs cancer biotech. 

Spruce Biosciences raised $88 million from the likes of Abingworth and Omega Funds to take the drug to the next level: a late-stage study in adults.